Netherlands· NL-c4931df5f47c
SAYANA 104 mg/0,65 ml suspensie voor injectie
A medroxyprogesterone product containing medroxyprogesteronacetaat, registered in Netherlands by Pfizer B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Medroxyprogesterone is registered in 11 of 19 countries.
Countries holding a registration under ATC G03AC06 (medroxyprogesterone), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Medroxyprogesterone · ATC G03AC06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MEDROXYPROGESTERONACETAAT
- Manufacturer
- Pfizer B.V.
- Country
- Netherlands (NL)
- ATC code
- G03AC06
- ATC class
- Medroxyprogesterone
- Defined daily dose
- 1.67 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id35305
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
245 interactions on record for medroxyprogesterone.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Medroxyprogesterone · interactions on record
245 records
- 21 severe
- 213 moderate
- 7 minor
Most severe, free to view
- Tranexamic acidB02AA02severe
- BosentanC02KX01severe
- GriseofulvinD01AA08severe
- GriseofulvinD01BA01severe
4 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Medroxyprogesterone in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesDepo-SubQ ProveraPharmacia & Upjohn Company LLC
- United KingdomAdgyn Medro 5mg tabletsKyowa Kirin Ltd
- FinlandCykrinaWyeth Medica Ireland
- BelgiumDepo-Provera 1000, 1000 mgPfizer
- CzechiaDEPO-PROVERAPfizer, spol. s r.o., Praha
- CanadaAA-MEDROXYAA PHARMA INC
- Japanメドロキシプロゲステロン酢酸エステル東和薬品
- SwedenDepo-Provera 150 mg/ml Injektionsvätska, suspensionPfizer AB
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Depocon, Farlutal
- Belgium · Depo-Provera, Provera
- Bulgaria · Фарлутал
- Czechia · Depo-Provera, Provera
- Germany · Depo-Clinovir, Mpa
- Denmark · Depo-Provera, Provera
- Estonia · Farlutal
- Spain · Depo-Progevera, Progevera
- Finland · Farlutal, Provera
- France · Depo Prodasone, Depo Provera
- United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
- Croatia · Provera
- Hungary · Depo-Provera, Provera
- Ireland · Depo-Provera, Provera
- Iceland · Depo-Provera
- Italy · Depo-Provera, Farlutal
- Luxembourg · Depo-Provera, Provera
- Latvia · Depo-Provera
- Norway · Depo-Provera, Provera
- Poland · Depo-Provera, Provera
- Portugal · Depo-Provera 150
- Sweden · Depo-Provera, Provera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd6ba476-71b5-4ffe-b65c-a3b377fe094b GET /v1/drugs/cd6ba476-71b5-4ffe-b65c-a3b377fe094b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Suspensie voor injectie",
"route": "Subcutaan gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h35305_smpc.pdf",
"strength": null,
"atc_label": "Medroxyprogesterone",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg35305",
"excipients": [
"DINATRIUMWATERSTOFFOSFAAT 12-WATER (E 339)",
"MACROGOL",
"METHIONINE, (L-)",
"METHYLPARAHYDROXYBENZOAAT (E 218)",
"NATRIUMCHLORIDE",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"NATRIUMHYDROXIDE (E 524)",
"POLYSORBAAT 80 (E 433)",
"POVIDON (E 1201)",
"PROPYLPARAHYDROXYBENZOAAT",
"WATER, GEZUIVERD",
"ZOUTZUUR (E 507)"
],
"substances": [
"MEDROXYPROGESTERONACETAAT"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h35305.pdf",
"authorised_at": "2007/11/23",
"procedure_number": "NL/H/4885/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "35305",
"additional_monitoring": "N"
}See everything about medroxyprogesterone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.